CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes

Citation for published version (APA):

Document status and date:
Published: 15/11/2012

DOI:
10.1042/BJ20120060

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 15 Sep. 2023
CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes

Yeliz ANGIN*1,2, Laura K. M. STEINBUSCH†, Peter J. SIMONS‡, Sabrina GREULICH§, Nicole T. H. HOEBERS*, Kim DOUMA*, Marc A. M. J. VAN ZANDVOORT*, Will A. COUMANS*, Wino WIJNEN*, Michaela DIAMANT‡, D. Margriet OUWENS‡, Jan F. C. GLATZ* and Joost J. F. P. LUIKEN*

*CARIM, Maastricht University, Universiteitsring 50, P.O. Box 616, 6200 MD Maastricht, The Netherlands, †Bioscero BV, Yalealaan 46, 3894 CM Utrecht, The Netherlands, ‡German Diabetes Center, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany, and §Diabetes Center, VUmc, Postbus 7057, 1007 MB Amsterdam, The Netherlands

An increased cardiac fatty acid supply and increased sarcolemmal presence of the long-chain fatty acid transporter CD36 are associated with and contribute to impaired cardiac insulin sensitivity and function. In the present study we aimed at preventing the development of insulin resistance and contractile dysfunction in cardiomyocytes by blocking CD36-mediated palmitate uptake. Insulin resistance and contractile dysfunction were induced in primary cardiomyocytes by 48 h incubation in media containing either 100 nM insulin (high insulin; HI) or 200 µM palmitate (high palmitate; HP). Under both culture conditions, insulin-stimulated glucose uptake and Akt phosphorylation were abrogated or markedly reduced. Furthermore, cardiomyocytes cultured in each medium displayed elevated sarcolemmal CD36 content, increased basal palmitate uptake, lipid accumulation and decreased sarcomere shortening. Immunochemical CD36 inhibition enhanced basal glucose uptake and prevented elevated basal palmitate uptake, triacylglycerol accumulation and contractile dysfunction in cardiomyocytes cultured in either medium. Additionally, CD36 inhibition prevented loss of insulin signalling in cells cultured in HP, but not in HI medium. In conclusion, CD36 inhibition prevents lipid accumulation and lipid-induced contractile dysfunction in cardiomyocytes, but probably independently of effects on insulin signalling. Nonetheless, pharmacological CD36 inhibition may be considered as a treatment strategy to counteract impaired functioning of the lipid-loaded heart.

Key words: cardiac metabolism, CD36, diabetes, insulin resistance, lipid accumulation.

INTRODUCTION

Increased cardiac lipid content has been associated with pathophysiological conditions, such as cardiac insulin resistance and contractile dysfunction, which may lead to the development of diabetic cardiomyopathy [1–3]. Cardiac lipid accumulation occurs as a result of elevated LCFA (long-chain fatty acid) supply [4] and/or increased uptake of LCFA [5–7]. Excessive entry of LCFA into cardiomyocytes provides increased substrates for mitochondrial LCFA oxidation. When the flux of incoming LCFA exceeds the mitochondrial β-oxidation capacity, LCFA will increasingly be stored as triacylglycerols and converted into bio-active metabolites such as diacylglycerols. Notably, there is a strong correlation between triacylglycerol storage and insulin resistance [8,9]. Moreover, diacylglycerols have been regarded to be causal to the development of insulin resistance through activation of PKC (protein kinase C)-mediated serine/threonine phosphorylation of the insulin receptor substrate, thereby impairing downstream insulin signalling [10].

Glucose and LCFA are the major energy substrates for the heart. Cardiac substrate uptake is dependent on plasma glucose and LCFA concentrations, as well as the sarcolemmal presence of glucose and LCFA transporters [7,11]. The main GLUT (glucose transporter) in the heart is GLUT4, whereas LCFA uptake is largely mediated by CD36 [12]. Also other LCFA transporters have been found to be present in the heart, such as members of the family of FATPs (fatty acid transporter proteins), but these proteins have a minor role in bulk uptake of LCFA into the heart [7]. Insulin is a major physiological stimulator of cardiac glucose and fatty acid uptake. Insulin-stimulated glucose uptake is due to GLUT4 translocation from intracellular compartments to the sarcolemma via a vesicle-mediated process [12–14]. A similar vesicle-mediated process is also responsible for CD36 translocation from intracellular compartments to the sarcolemma, which entirely accounts for insulin-stimulated LCFA uptake [12]. Accordingly, in cardiomyocytes from CD36-knockout mice, insulin-induced CD36 translocation is completely abolished [15].

The expression of CD36 in the heart is not changed in rodent models of insulin resistance. However, this transporter has been shown to permanently relocate from intracellular stores to the sarcolemma. This CD36 relocation will cause chronically elevated LCFA uptake into the heart, followed by myocellular lipid accumulation, and consequently insulin resistance [7,16,17]. Ultimately, permanent sarcolemmal CD36 relocation may lead to cardiac dysfunction [16]. Accordingly, ablation of CD36 has been shown to preserve cardiac function in Western diet-fed mice [18], and also in mice suffering from PPARα (peroxisome-proliferator-activated receptor α) overexpression-induced lipotoxicity [19]. Taken together, CD36 and its increased abundance at the sarcolemma play a key role in the development of high-fat diet-induced cardiac dysfunction.

CD36 is a multifactorial protein and has different functions in different cell types. Several endogenous CD36 ligands (LCFA, thrombospondin-1 and oxidized low-density lipoproteins) with different binding regions on the extracellular domain of CD36 are known [20–22]. In addition, synthetic CD36-specific binding...
molecules [SSO (sulfo-N-succinimidyl oleate), hexarelin and EP80317] and antibodies have been introduced [23,24]. Sulfo-N-succinimidyl esters of LCFA s have proven to block initial LCFA uptake into heart and muscle [25]. However, they are not useful in long-term experiments because of their chemical instability [24]. In the search for other CD36 ligands that interfere with the fatty acid transport function of CD36, we tested whether hexarelin, EP80317 and anti-CD36 mAbs (monoclonal antibodies) would inhibit short-term LCFA uptake into cardiomyocytes prior to testing their protective potential against the detrimental effects of cardiomyocytic lipid overload.

To test the putative preventive effect of CD36 ligands on cardiomyocyte lipid accumulation, insulin resistance and contractile dysfunction, we first needed to establish suitable culture conditions in which cardiomyocytes develop excessive lipid storage and loss of insulin signalling and contractile function. For this, we chronically exposed rat primary cardiomyocytes to two different media. One medium contained a high concentration of insulin (HI), because insulin is known to induce CD36 translocation to the sarclemma and thereby increase LCFA uptake and lipid accumulation. It is also known that chronic insulin treatment induces loss of insulin signalling in cardiomyocytes [26]. A second medium contained a high concentration of palmitate (HP), which is known to reduce contractile function [27]. As a result, cardiomyocytes were cultured in a HI or a HP medium with/without a CD36-blocking compound. Then, we evaluated the cultured cardiomyocytes on the presence of surface CD36, glucose and LCFA uptake, insulin signalling, myocellular lipid content and contractile function. We describe in the present paper that inhibition of CD36-mediated LCFA uptake by a CD36-blocking compound prevents lipid accumulation and loss of sarcomere shortening in these cultured cardiomyocytes.

MATERIALS AND METHODS

Materials

[14C]Palmitic acid and [3H]deoxyglucose were obtained from GE Healthcare. [1H]Chloroquine was from Moravek Biochemicals. Laminin and insulin were purchased from Sigma. BSA (fraction V), dependent on the application, was derived from MP Biomedicals (for cell isolation and incubation purposes) or from Sigma (other purposes). Collagenase type II was from Worthington. SSO was synthesized in our laboratory [28] and EP80317 was from Bio-Connect (special production by Peptides International). Hexarelin was a gift from Professor J. Heemskerk (CARIM, Maastricht, The Netherlands). The anti-CD36 mAb clone 63 (anti-CD36-c163; also known as clone CRF D2717) was from BD Biosciences, and was provided by Bioceros BV. The anti-CD36 mAb clone 10E10 (anti-CD36-c110E10) was produced by Bioceros BV.

Experimental animals

Male Lewis rats (200–250 g), were purchased from Charles River Laboratories and were used for cardiomyocyte isolation. All animals were fed ad libitum and kept under normal 12 h/12 h dark–light cycles. All procedures were approved by the Experimental Animal Committee of Maastricht University, Maastricht, The Netherlands.

Cardiomyocyte isolation and culturing

Cardiomyocyte isolations were performed as described previously [29] with the only difference being the sterile conditions that were taken into account for subsequent culturing. After isolation of cardiomyocytes, 200 000 cells/well were routinely seeded in laminin-coated six-well plates (9.6 cm²), unless specified otherwise. After 90 min adhesion in modified Krebs–Ringer medium [30] supplemented with 0.45% BSA, the adhesion medium was replaced with control medium [M199 supplemented with 5 mM creatine monohydrate, 3.2 mM carnitine hydrochloride, 3.1 mM taurine, 100 units/ml penicillin and 10 mg/ml streptomycin and 20 μM palmitate (palmitate/BSA, 0.3:1)]. HI medium (control medium supplemented with 100 mM insulin) or HP medium (control medium with an additional 200 μM palmitate (palmitate/BSA, 3:1)]. Cells were cultured for 48 h and for measurements of short-term insulin effects cardiomyocytes were washed with modified Krebs–Ringer solution supplemented with 0.45% BSA and 1 mM CaCl2 (medium A) and left untreated for 30 min (explained in detail in the Results section).

Measurement of substrate uptake

We measured uptake of [1-14C]palmitate (in complex with BSA) and [3H]deoxyglucose into freshly isolated cardiomyocytes [30] as well as into cardiomyocytes in culture [13], as described previously. With respect to freshly isolated cardiomyocytes, cells were pre-incubated with anti-CD36-specific binding molecules (500 μM SSO, 100 μM EP80317, 20 μM hexarelin, 0.83 μg/ml anti-CD36-c163 and 1.7 μg/ml anti-CD36-c110E10) at 37 °C while shaking for 20 min, and subsequently incubated without/with oligomycin (5 μM) for an additional 20 min. Then, a mixture of [1H]glucose and [14C]palmitate was added for the last 5 min of incubation and radioactivity was measured in scintillation fluid (Opti-Fluor, PerkinElmer).

For cardiomyocytes that had been cultured for 2 days, a mixture of [1H]glucose and [14C]palmitate was added for 10 min directly following a 15 min incubation period with/without insulin (100 nM). Then, cells were washed with Stop medium (modified Krebs–Ringer buffer with 1 mM Ca2+ and 0.2 mM phloretin) on ice, lysed in sample buffer [40% glycerol, 0.25 M Tris and 1 M DTT (dithiothreitol)] and radioactivity was measured in scintillation fluid (Opti-Fluor, PerkinElmer).

Detection of phosphorylation of enzymes within the insulin signalling network

Following a 15 min treatment with/without insulin (100 nM), cells were lysed in sample buffer (40% glycerol, 0.25 M Tris, 1 M DTT and 1.5 mM Bromophenol Blue) and used for protein detection by SDS/PAGE (20 μg of protein per lane), followed by Western blotting, as described previously [31]. Antibodies against phospho-Ser473-Akt, Akt, phospho-Ser473-GSK3β (glycogen synthase kinase 3β) and GSK3β were purchased from Cell Signaling Technology, against phospho-Thr34, Thr44/42, AS160 (Akt substrate of 160 kDa) was purchased from Upstate Biotechnology, against CD36 was purchased from GenTex, against GLUT4 and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was purchased from Abcam, and against caveolin 3 was purchased from BD Transduction Laboratories. The anti-CD36 monoclonal antibody M025 was a gift from Dr. N.N. Tandon (Thrombosis Research Laboratory, Otsuka Maryland Medicinal Laboratories Rockville, MS, U.S.A.) and was used only for Western blotting. Western blot images were analysed with a molecular imager (Chemidoc XRS, Bio-Rad Laboratories) and quantified with Quantity One® (Bio-Rad Laboratories).
Measurement of sarcomere shortening and Ca\(^{2+}\) fluxes

For measurement of sarcomere shortening and Ca\(^{2+}\) fluxes, cells were cultured on 35-mm high dishes with an elastic surface from Ibidi. After 2 days of culture, cells were preloaded with fura 2/AM (Merck Chemicals) for 25 min at room temperature (24°C), washed twice with control M199 and then incubated for 20 min with M199. Subsequently, contractile function and Ca\(^{2+}\) transients were analysed in cells showing an intact rod-shaped morphology and sarcomere length >1.6 μm as described previously [32]. Before the start of measurement, cells were paced with bipolar pulses of 5 ms duration at 1 Hz. The cytosolic Ca\(^{2+}\) concentration was monitored as a ratio of the fluorescence emission peaks at 340 and 380 nm. Under each experimental condition, data files were recorded of ten consecutive beats for at least eight different cells. Sarcomere shortening and Ca\(^{2+}\) transients were measured with a fluorescence system from IonOptix and calculated using IonWizard (IonOptix).

Myocellular triacylglycerol and diacylglycerol contents

For measurement of intramyocellular lipid content, cardiomyocytes were cultured in 55 cm\(^2\) glass petri dishes with a 1 x 10\(^5\) cell density. Intramyocellular lipids were determined after 2 days of culturing as described previously [33]. Briefly, samples containing 400 μg of protein were used for intracellular lipid extraction in methanol/chloroform, and an internal standard and water were added. Afterwards TLC was used to separate lipids. Bands were resolved with a hexane/diethylether/propanol (87:10:3) resolving solution. Triacylglycerol and diacylglycerol bands were detected with a molecular imager (ChemiDoc XRS, Bio-Rad Laboratories) and analysed with Quantity One® (Bio-Rad Laboratories).

Sarcolemmal presence of CD36

Following a 15 min treatment with/without insulin (100 nM), cells were incubated for 10 min with 2 μg/ml anti-CD36-c163, which is known to cross-react with rat CD36, and FITC-labelled rabbit-anti-mouse IgA secondary antibodies (1:500 dilution; Rockland). Cardiomyocytes were co-cultured with adhesion medium and then the viable cardiomyocytes were imaged using the Leica SP5 imaging platform in two-photon mode (Leica Microsystems) with the emission filters optimized for FITC detection. Images were processed with ImageJ (NIH). Cardiomyocytes were kept at 37°C during incubation and imaging.

Statistics

Differences among the data obtained from five to eight experiments are presented as means ± S.E.M. Statistical differences between groups of observations were evaluated by unpaired Student’s t test, one-way ANOVA or two-way ANOVA, depending on the groups compared. P values equal to or less than 0.05 were considered as significant.

RESULTS

Anti-CD36-c163 treatment inhibits LCFA uptake in freshly isolated cardiomyocytes

Our first aim was to select a CD36 ligand that would inhibit LCFA uptake into cardiomyocyte cultures. Therefore we tested the ability of hexarelin (100 μM), EP80317 (20 μM) and two distinct anti-CD36 antibodies, i.e. anti-CD36-c163 (0.83 μg/ml) and anti-CD36-c110E10 (1.7 μg/ml), to block short-term LCFA uptake into cardiomyocytes under basal conditions, and found that only anti-CD36-c163 was effective (Figure 1A). In addition, the specific CD36 inhibitor SSO modestly inhibited basal LCFA uptake, as described previously [23]. As expected, the putative LCFA uptake-blocking effects of the selected CD36 ligands can be best appreciated under conditions in which CD36 has a large contribution to the LCFA uptake rate in cardiomyocytes. Therefore we also tested the ability of these CD36 ligands to inhibit LCFA uptake into cardiomyocytes treated with the F,Fr,ATPase inhibitor oligomycin, because oligomycin treatment is known to enhance the contribution of CD36 to total LCFA uptake into rat cardiomyocytes from approximately 50% to >80% [28]. In agreement with the effects under basal conditions, only SSO and anti-CD36-c163 significantly inhibited LCFA uptake under oligomycin stimulation (Figure 1A). We then tested lower and higher concentrations of the CD36 ligands used on LCFA uptake in cardiomyocytes. In the case of EP80317 and hexarelin, higher concentrations impaired cell viability (results not shown). In the case of anti-CD36-c110E10 (results not shown) and anti-CD36-c163 (Figure 1B), no further inhibitory effect was observed at higher concentrations, whereas lower anti-CD36-c163 concentrations did not significantly inhibit LCFA uptake. In contrast with LCFA uptake, both SSO and anti-CD36-c163 did not inhibit basal or oligomycin-stimulated glucose uptake (Figure 1), thereby providing evidence that their inhibitory effects on cardiac substrate uptake are selective for LCFA uptake. Because SSO is not suitable as a long-term blocker of LCFA uptake [24], we selected anti-CD36-c163 (0.83 μg/ml) to chronically inhibit palmitate uptake into primary cardiomyocyte cultures.

Short-term insulin effect on substrate uptake disappears after 30 min

To assay insulin-stimulated glucose and LCFA uptake, we treated cardiomyocytes with insulin for 15 min prior to substrate-uptake measurements. However, in the case of culturing cardiomyocytes in HI medium for 2 days, chronic and short-term insulin effects might be present at the same time. To fully appreciate the chronic effects of insulin on Akt phosphorylation and substrate uptake, the short-term effect of insulin must have completely disappeared. Therefore we determined the disappearance time of short-term insulin effects on glucose and, for comparison, on LCFA uptake into basally cultured cardiomyocytes. Cardiomyocytes were stimulated with insulin (100 nM) for 15 min and directly assayed for substrate uptake or the stimulus medium containing insulin was washed away and substrate uptake was measured at several time points (Figure 2). First, insulin significantly increased both glucose and palmitate uptake rates (Figure 2). Secondly, glucose uptake returned to basal levels after 15 min and palmitate uptake returned to basal levels after 30 min. Therefore, in the following experiments, cells were washed after 48 h of culturing. Then, control medium was added to all wells, and we waited for 30 min before starting insulin-sensitivity measurements.

Establishment of lipid-loaded and insulin-resistant cardiomyocytes with decreased contractile activity

Cardiomyocytes were exposed to HI or HP medium to induce myocellular insulin resistance. One of the initial steps in acquisition of myocellular insulin resistance is the permanent relocation of CD36 to the sarcolemma [34]. The presence
of sarcolemmal CD36 was measured in viable cells by twophoton microscopy. First, it was confirmed that this method could be successfully applied in our experimental setting, because short-term (15 min) insulin treatment of basally cultured cardiomyocytes promoted the well-recognized increase in CD36 presence at the sarcolemma (Figure 3A), which is due to translocation from intracellular stores [34]. Additionally, HI and HP medium enhanced the presence of sarcolemmal CD36 (Figure 3B). However, total (i.e. sum of intracellular and sarcolemmal) CD36 protein expression was not altered after culturing of cardiomyocytes in HI or HP medium (Figure 3C), implying that upon either of the insulin-resistance-inducing conditions CD36 is permanently relocated from intracellular stores to the sarcolemma. Additionally, both insulin-resistance-inducing media did not alter myocellular GLUT4 expression (Figure 3C).

Basally cultured cardiomyocytes displayed a 3.8-fold increase in glucose uptake and a 1.5-fold increase in palmitate uptake upon insulin treatment. Cardiomyocytes cultured in either HI or HP medium showed no change in basal glucose uptake (Figure 4A). In contrast, these cardiomyocytes exhibited elevated basal LCFA uptake (amounting to 1.4-fold and 1.6-fold respectively)
CD36 inhibition prevents contractile dysfunction

Figure 3 Effects of culturing under insulin-resistance-inducing conditions on cell-surface content and total expression levels of CD36 in cardiomyocytes

(A) For verification of the suitability of two-photon microscopy to visualize changes in cell-surface localization of CD36, cells were short-term (15 min) treated with 100 nM insulin to positively confirm the well-described insulin-induced CD36-translocation event. CD36 was detected upon FITC labelling. Representative images are shown (n = 3). (B) Cardiomyocytes were cultured in control medium, or in HI or HP medium for 48 h, and then used for microscopic detection of CD36 (n = 3). (C) Protein expression of GLUT4 and CD36, and caveolin 3 (Cav3, loading control) was measured in cell lysates from cardiomyocytes cultured in control (C), HI or HP medium without or with (C+, HI+, HP+) 0.83 μg/ml anti-CD36-cl63. Representative blots are shown (n = 3).

compared with basally cultured cells. In addition, cardiomyocytes cultured in either HI or HP medium displayed a loss of insulin-stimulated glucose and LCFA uptake (Figure 4B).

For evaluation of insulin signalling, phosphorylation of Akt and its two direct substrates, AS160 and GSK3β, was assessed. In basally cultured cardiomyocytes, short-term insulin addition increased Akt Ser473 phosphorylation, AS160 phosphorylation and GSK3β Ser9 phosphorylation by 4.4-fold, 3.8-fold and 2.5-fold respectively (Figure 5B). Insulin-stimulated signalling was completely lost in cardiomyocytes cultured in HI medium, and largely reduced in cardiomyocytes cultured in HP medium. In this latter instance, only a residual 3.1-fold insulin-stimulation of Akt Ser473 phosphorylation was observed, whereas induction of GSK3β and AS160 was completely abrogated (Figure 5B). These decreases in insulin signalling were not accompanied by changes in total expression of Akt or of downstream substrates (Supplementary Figure S1 at http://www.BiochemJ.org/bj/448/bj4480043add.htm).

With respect to myocellular lipid accumulation, cardiomyocytes cultured in HI or HP medium displayed increased triacylglycerol content (1.6-fold and 2.3-fold respectively) compared with basally cultured cardiomyocytes (Figure 6), but we did not observe changes in diacylglycerol stores (Figure 6).

To investigate whether exposure to HI or HP medium leads to physiological dysfunction of cardiomyocytes, we analysed the kinetics and amplitude of the contraction, and shortening and re-lengthening rates, as well as peak sarcomere shortening. Compared with basally cultured cardiomyocytes, peak sarcomere shortening decreased by 38% and 62% during culturing in HI and HP medium respectively (Figure 7A). Departure velocity and return velocity of contraction were also reduced by culturing in HI and HP medium (departure velocity, −45% and −62% respectively; return velocity, −65% and −70% respectively). Intracellular Ca2+ fluxes (velocity of Ca2+ increases and decreases, and peak fura 2 fluorescence signal) were unchanged in cardiomyocytes cultured in either medium (Figure 7B).

Thus cardiomyocytes cultured in HI or HP medium displayed elevations in sarcolemmal CD36 presence, basal LCFA uptake and myocellular triacylglycerol content. In addition, cardiomyocytes cultured in either medium showed loss of insulin-stimulated substrate uptake, insulin signalling and sarcomere shortening, and hence displayed hallmark features of lipid-induced insulin resistance and contractile dysfunction.

Effects of anti-CD36-cl63 treatment on prevention of lipid accumulation and development of insulin resistance

Anti-CD36-cl63 was used to evaluate the effects of a blockade of CD36-mediated LCFA uptake on prevention of the development of insulin resistance and contractile dysfunction in cardiomyocytes cultured in HI or HP medium. Anti-CD36-cl63 was added at the start of the 2 days of culturing of cardiomyocytes under basal or insulin-resistance-inducing conditions, and was removed by washing the cardiomyocytes prior to the measurements of short-term glucose and palmitate uptake. The lack of an effect of anti-CD36-cl63 on basal and insulin-stimulated palmitate uptake into basally cultured cardiomyocytes (Figure 4) indicates that this antibody has effectively been washed away (as shown with two-photon microscopy, see Supplementary Figure S2 at http://www.BiochemJ.org/bj/448/bj4480043add.htm), and suggests that there has been no compensatory up-regulation of CD36 (in agreement with Figure 1C) or of other...
Treatment with anti-CD36-cl63 did not alter insulin-stimulated phosphorylation under all three culture conditions (control, 3-fold; HI medium, 3.2-fold; HP medium, 1.7-fold) (Figure 5). Treatment with anti-CD36-cl63 did not alter insulin-stimulated Akt phosphorylation in basally cultured cardiomyocytes, and did not prevent loss of insulin-stimulated Akt phosphorylation in cardiomyocytes cultured in HI medium. However, treatment with anti-CD36-cl63 was successful in preventing loss of insulin-stimulated Akt phosphorylation in cardiomyocytes cultured in HP medium. Overall, changes in Akt Ser<sup>473</sup> phosphorylation were largely prevented by changes in GSK3β Ser<sup>9</sup> phosphorylation, and to a lesser extent by changes in AS160 phosphorylation.

With respect to intramyocellular lipid accumulation, treatment with anti-CD36-cl63 robustly reduced triacylglycerol content in cardiomyocytes cultured in control medium, and completely prevented the increase in triacylglycerol storage upon culturing in HI or HP medium (Figure 6). There was no effect of treatment with anti-CD36-cl63 on myocardial diacylglycerol content (Figure 6).

With respect to parameters of contractile function, treatment with the anti-CD36-cl63 had no effect on sarcomere shortening or intracellular Ca<sup>2+</sup> oscillations in basally cultured cardiomyocytes. Treatment of primary cardiomyocytes with anti-CD36-cl63 totally or largely prevented the decrease in peak sarcomere shortening in HI- or HP-cultured cardiomyocytes respectively (Figure 7). Additionally, shortening and relengthening rates were partially retained upon treatment of HI-cultured cardiomyocytes with anti-CD36-cl63. In contrast, intracellular Ca<sup>2+</sup> oscillations were not altered by treatment with anti-CD36-cl63 (Figure 7).

We also tested the effects of anti-CD36-cl10E10, which detects CD36 on Western blot (Supplementary Figure S3 at http://www.BiochemJ.org/bj/448/bj4480043add.htm), but which failed to block short-term LCFA uptake (Figure 1A), on glucose uptake and contractile function in cardiomyocytes cultured in basal, HI and HP media. In contrast with anti-CD36-cl63, anti-CD36-cl10E10 did not increase basal glucose uptake under the three culturing conditions or restore peak sarcomere shortening in HI-cultured cardiomyocytes (Supplementary Figure S3). Hence, the beneficial effects of anti-CD36-cl63 cardiomyocytes exposed to lipotoxic conditions are probably not due to simply binding to CD36, but rather due to a blockade of the transport function of CD36.

In summary, treatment of cardiomyocytes cultured in HI or HP medium with anti-CD36-cl63 prevented lipid accumulation and lipid-induced contractile dysfunction. However, treatment with anti-CD36-cl63 only protected insulin signalling in cardiomyocytes cultured in HP medium, and not when cultured in HI medium.

**DISCUSSION**

In the present paper we described the preventive action of a pharmacological blockade of LCFA uptake in the development of insulin resistance and contractile dysfunction in cardiomyocytes. Although there are many studies reporting on the ability of lipids to decrease insulin signalling and to alter substrate utilization in cellular systems, including cardiomyocytes, none of these studies have proposed to restore the maladaptive changes by blocking protein-mediated cellular LCFA uptake. In the present study, we investigated the suitability of CD36 as a target to restore insulin sensitivity and contractile parameters in cultures of cardiomyocytes exposed to insulin-resistance-inducing conditions. First, a variety of structurally unrelated compounds reported to inhibit CD36 function were screened for their ability to inhibit LCFA uptake into primary cardiomyocytes. Secondly, we established that cardiomyocytes cultured in HI or HP medium displayed key features of lipid-induced insulin resistance [34]. Finally, we demonstrated that inhibition of CD36-mediated LCFA uptake was able to prevent lipid accumulation and contractile dysfunction in cardiomyocytes cultured under insulin-resistance-inducing conditions.
Cardiomyocytes were cultured in control (C), HI or HP medium in the absence or presence of 0.83 μg/ml anti-CD36-cl63. Upon 2 days culturing, cells were allowed to recover for 30 min prior to short-term (15 min) insulin (100 nM) addition and subsequent Western blotting for phosphorylation of Akt (pAkt), AS160 (pAS160) and GSK3β (pGSK3β). Representative blots are shown in (A). Quantification of the signals is shown in (B). Values are means ± S.E.M. (n = 5). *P < 0.05, insulin effect; #P < 0.05, medium effect; ^P < 0.05, anti-CD36 effect.

**Anti-CD36-cl63 potently inhibits LCFA uptake into primary cardiomyocytes**

SSO is the most widely established inhibitor of CD36-mediated LCFA uptake, but its use in long-term incubations is not feasible because of its relatively short half-life in aqueous solutions [24]. Nonetheless, the use of SSO in short-term LCFA uptake studies confirmed that maximally stimulated LCFA uptake in these primary cardiomyocytes is largely CD36-dependent. The CD36-specific thrombospondin-binding peptide inhibitors hexarelin and EP80317 did not affect LCFA uptake, demonstrating that the thrombospondin-binding domain of CD36 is not involved in LCFA transport or does not overlap with the LCFA-binding pocket of CD36 [35,36]. Hence both peptides are likely to be
Chronic palmitate treatment of cardiomyocyte cultures enhanced measured. In the present study, chronic insulin treatment as well as cultures [26] but, again, LCFA transport and transporters were not also been used to induce insulin resistance in cardiomyocyte have not yet been investigated. Chronic insulin stimulation has long-term effects on LCFA transport, transporters and storage decreased insulin-stimulated glucose uptake [39–41]. However, resistance at the level of decreased insulin signalling and/or with saturated LCFA species has been shown to induce insulin resistance (J.J.F.P. Luiken and A. Bonen, unpublished work). Taken together, the results suggest that the anti-CD36-cl63 is a valuable in vitro tool to test whether CD36-mediated LCFA uptake would be a target for offering protection to lipid-overloaded cardiomyocytes against the development of insulin resistance and contractile dysfunction.

Development of a cardiomyocyte model for lipid-induced insulin resistance

Long-term incubation of cell lines or primary cell cultures with saturated LCFA species has been shown to induce insulin resistance at the level of decreased insulin signalling and/or decreased insulin-stimulated glucose uptake [39–41]. However, long-term effects on LCFA transport, transporters and storage have not yet been investigated. Chronic insulin stimulation has also been used to induce insulin resistance in cardiomyocyte cultures [26] but, again, LCFA transport and transporters were not measured. In the present study, chronic insulin treatment as well as chronic palmitate treatment of cardiomyocyte cultures enhanced the presence of CD36 at the sarcolemma in concordance with elevated basal LCFA uptake and triacylglycerol accumulation. Simultaneously, insulin-stimulated phosphorylation of proteins in the insulin signalling cascade and insulin-stimulated glucose and LCFA uptake were lost or markedly reduced in chronic insulin- or palmitate-treated cardiomyocytes. These results indicate that both chronic conditions induce key features of insulin resistance in this in vitro cardiomyocyte model. Yet there are some subtle differences in insulin-treated and palmitate-treated cardiomyocytes concerning these features of insulin resistance: (i) lipid accumulation in palmitate-treated cells is 2-fold greater than in insulin-treated cells, whereas inhibition of insulin signalling is less extensive in palmitate-treated cells, and (ii) inhibition of insulin-stimulated substrate uptake is almost identical in both insulin- and palmitate-treated cardiomyocytes. This demonstrates that there is no linear relationship between lipid accumulation, impairment of insulin signalling and of insulin-stimulated glucose uptake. Another striking feature of the HI- and HP-cultured cells is that the increase in myocellular triacylglycerol storage is not accompanied by increased diacylglycerol levels. This is different from the concomitant increases in myocellular diacylglycerol and triacylglycerol contents in rodents fed with high-fat diets for several weeks (e.g. see [13]). This is probably related to the much shorter (i.e. 48 h) exposure of the cells to lipotoxic conditions, in which time the diacylglycerol and triacylglycerol stores might not have reached full equilibrium yet. However, importantly, given that the cells are insulin resistant, it can be deduced that diacylglycerols do not contribute to the acquisition of insulin resistance in these cultured cardiomyocytes.

With respect to cardiomyocyte contractility, culturing of cardiomyocytes in HI or HP medium impaired contractile amplitude. This is in agreement with recent findings that exposure of freshly isolated adult mouse cardiomyocytes to palmitate rapidly reduced unloaded fractional cell shortening [27], and in line with the currently accepted idea that insulin resistance is causal to contractile dysfunction [42]. There is more controversy about the association of insulin resistance with disturbance of Ca2+ dynamics. In our experiments Ca2+ oscillations were unchanged in cells cultured in HI and HP medium. This is in agreement with the lack of change in kinetics and amplitude of Ca2+ transients in cardiomyocytes from mice fed a high-fat diet [43]. However, cardiomyocytes from insulin resistant sucrrose-fed mice and ob/ob mice displayed decreased Ca2+ oscillations [44,45]. Nonetheless, sarcomere shortening is considered as a better marker of mechanical output for evaluating cardiomyocyte function [46]. Interestingly, the alterations in contractile function were proportional to the amount of myocellular triacylglycerol accumulation, because HP-cultured cardiomyocytes showed greater dysfunction and greater triacylglycerol accumulation than in HI-cultured cells. This supports the concept that myocellular accumulation of lipids is causal to contractile dysfunction.

In conclusion, both HI and HP medium provide suitable culturing conditions for inducing insulin resistance and contractile dysfunction in cardiomyocytes via myocellular lipid overload.

Inhibition of CD36-mediated LCFA uptake prevents reduction of insulin sensitivity and contractile function in lipid-overloaded cardiomyocytes

The main purpose of the present study was to prevent the development of lipid-induced insulin resistance and contractile dysfunction by inhibition of CD36-mediated LCFA uptake.

First, we investigated the metabolic effects of inhibition of CD36-mediated LCFA uptake in basically cultured insulin-sensitive
Figure 7  Effect of anti-CD36-cl63 on contractile functions of cardiomyocytes cultured under insulin-resistance-inducing conditions

Cardiomyocytes were cultured in control, HI or HP in the absence or presence of 0.83 μg/ml anti-CD36-cl63. After 2 days culturing, cardiomyocytes were used for analysis of the following parameters: (A) sarcomere shortening and (B) Ca²⁺ fluxes. (A) Departure velocity of contraction, peak sarcomere shortening and return velocity of contraction. (B) Velocity of cytosolic Ca²⁺ increases, peak fura 2 fluorescence signal and velocity of cytosolic Ca²⁺ decreases. Values are means ± S.E.M. for at least ten independent experiments. #P < 0.05, medium effect; ^P < 0.05, anti-CD36 effect.

cardiomyocytes. Treatment of basally cultured cardiomyocytes with anti-CD36-cl63 enhanced basal glucose uptake, and insulin did not stimulate glucose uptake further, suggesting that insulin-stimulated glucose uptake contributes to increased basal glucose uptake in CD36-inhibited cardiomyocytes. This increased basal glucose uptake occurred in the absence of changes in GLUT4 expression, suggesting that a relocation of GLUT4 from intracellular insulin-responsive stores to the sarcolemma might explain this increase in basal glucose uptake. Furthermore, the anti-CD36cl63-induced increase in basal glucose uptake is likely to be due to a blockade of the transport function of CD36 rather than just binding to CD36. Namely, another anti-CD36 antibody, anti-CD36-cl10E10, unable to block the LCFA transport function, does not increase glucose uptake. This shows that merely binding to CD36 is not sufficient for a change in substrate switch towards glucose. Interestingly, the increase in basal glucose uptake was accompanied by an increase in phosphorylation of both Akt and its direct target AS160. Phosphorylation of AS160 will inhibits its Rab-GTPase activity, so that GLUT4 translocation-mediating Rab proteins will be re-activated. Subsequently, GLUT4 will be liberated from retention within the intracellular stores. Remarkably, insulin-stimulated Akt phosphorylation was retained in basally cultured cardiomyocytes treated with anti-CD36-cl63, which is in contrast with the loss of insulin-stimulated glucose uptake. Perhaps in these cardiomyocytes GLUT4 is already completely depleted from the intracellular storage compartments, including the insulin-responsive stores, so that extra phosphorylation of Akt and of AS160 upon insulin addition would be futile in this respect. Another explanation could come from a recent study in which it was shown that Akt is not the rate-limiting step of insulin-induced glucose uptake [47]. However, insulin-stimulated glucose uptake in these anti-CD36-cl63-treated cardiomyocytes was not further increased by additional stimulation of AMPK (AMP-activated protein kinase) signalling, whereas AMPK and insulin stimulation act synergistically in basally treated cardiomyocytes (Supplementary Figure S4 at http://www.BiochemJ.org/bj/448/bj4480043add.htm). This observation provides further evidence for the idea of depletion of intracellular GLUT4 storage upon a chronic CD36 blockade.

How anti-CD36-cl63 could trigger basal Akt phosphorylation in cardiomyocytes is a matter of speculation. Perhaps a pharmacological blockade of CD36 transport function prevents accumulation of LCFA metabolites that would inhibit kinases upstream of Akt or Akt itself. For instance, ceramides are known to directly inhibit Akt [48], and preventing their accumulation would therefore increase basal Akt phosphorylation. This would also assume that ceramide pools would more rapidly follow the changes in influx in LCFA than the diacylglycerols. Further research is needed to elucidate the molecular mechanisms behind increased basal Akt phosphorylation in anti-CD36-cl63-treated cardiomyocytes.

Treatment of cardiomyocytes cultured under both insulin-resistance-inducing conditions with anti-CD36-cl63 enhanced basal Akt/GSK3β phosphorylation and basal glucose uptake.
in a similar manner to basally cultured cardiomyocytes treated with anti-CD36-c163. More importantly, however, this treatment prevented myocardial lipid accumulation and loss of contractile function. Remarkably, treatment with anti-CD36-c163 prevented the loss of insulin-stimulated Akt/GSK3β phosphorylation in cardiomyocytes cultured in HP medium, but was not able to retain insulin signalling in cardiomyocytes cultured in HI medium. We have no explanation for these selective preventive effects of anti-CD36-c163 on insulin signalling and insulin-stimulated glucose uptake in one model of insulin resistant cardiomyocytes and not in the other. However, we may only conclude that the prevention of myocardial lipid accumulation can be connected to preservation of contractile function in the absence of preservation of insulin signalling. Possibly, the prevention of myocardial lipid accumulation might directly explain the anti-CD36 mAb-mediated preservation of contractile function. Namely, increased depositing of lipid droplets in between the contractile fibres could directly inhibit contraction mechanics, which is then prevented by blocking CD36-mediated LCFA uptake. Alternatively, the prevention of myocardial lipid accumulation would prevent the activation of lipid-activated transcription factors that would otherwise induce an unfavourable switch in the expression pattern of isoforms of contractile proteins. However, we cannot exclude the possibility that the protective effects of the anti-CD36 mAb are not related to inhibition of LCFA uptake. For instance, binding of anti-CD36-c163 to CD36 might induce intracellular signalling (e.g. Akt activation) that would directly or indirectly preserve contractile function of cardiomyocytes. Nonetheless, the finding that the anti-CD36 mAb prevents the reduction in contractile function in cardiomyocytes cultured under both insulin-resistance-inducing conditions provides powerful evidence that CD36 offers a suitable target to prevent the onset of cardiomyocyte dysfunction under these adverse conditions.

Conclusions

In addition to the previous findings in CD36-knockout mice that CD36-mediated LCFA uptake plays a key role in the development of lipid-induced insulin resistance and cardiac dysfunction [17,18], the results of the present study illustrate that a pharmacological blockade of CD36 is a treatment strategy to counteract lipid accumulation and to protect against loss of cardiac function. Specifically, the blockade of CD36-mediated LCFA uptake caused a substrate switch towards glucose and prevented lipid accumulation and decreases in contractile function in two in vitro models of lipid-induced cardiac insulin resistance. Increased cardiac glucose uptake is known to be involved in the development of cardiomyocyte hypertrophy, suggesting that proper titration of anti-CD36 treatment is necessary to avoid a total shift of cardiomyocyte metabolism towards glucose utilization.

CD36 is known to have a number of different functions in different mammalian cell types. Therefore a pharmacological CD36 inhibitor that would interfere with all of these functions would be unfavourable. However, a hypothetical agent that would selectively block the sarcolemmal LCFA transport function of CD36 would not have these adverse side effects, and would therefore be optimally suited to improve cardiac lipid overload and contractile dysfunction in vivo. In this respect, it has been speculated that the LCFA-binding pocket in the extracellular domain of CD36 is not overlapping with the docking sites of thrombospondin and oxidized low-density lipoprotein [35]. Therefore the LCFA-binding pocket might be the subject of a novel drug design strategy to specifically block CD36 transport function.

AUTHOR CONTRIBUTION

Yeliz Angin and Laura Steinbusch designed and performed the experiments, analysed the data and wrote the paper. Peter Simons and Marc van Zandvoort reviewed the paper before submission. Sabrina Greulich, Nicole Hoebers, Will Coumans, Wino Wijnen and Kim Douma performed experiments. Margriet Ouwens, Michaela Diamant and Jan Glatz edited the paper before submission. Joost Luiken designed the experiments and edited the paper before submission.

ACKNOWLEDGEMENTS

We thank Lei Ding, Jurriaan Hodzelmans and Pascal Vroemen for their technical assistance.

FUNDING

This work was supported by the Dutch Diabetes Research Foundation [grant number 2006.00.044], the EU European Cooperation in the field of Scientific and Technical Research (COST) Action BM0602 (Adipose tissue: a key target for prevention of the metabolic syndrome), CTTM, the Center for Translational Molecular Medicine, project PREDICT [grant number 01C-104], the Netherlands Heart Foundation and the Dutch Kidney Foundation.

REFERENCES


SUPPLEMENTARY ONLINE DATA

CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes

Yeliz ANGIN*1,2, Laura K. M. STEINBUSCH*1, Peter J. SIMONS†, Sabrina GREULICH‡, Nicole T. H. HOEBERS*, Kim DOUMA*, Marc A. M. J. VAN ZANDVOORT*, Wil A. COUMANS*, Wino WIJNEN*, Michaela DIAMANT§, D. Margriet OUWENS‡, Jan F. C. GLATZ* and Joost J. F. P. LUIKEN*

*CARIM, Maastricht University, Universiteitssingel 50, P.O. Box 616, 6200 MD Maastricht, The Netherlands, †Bioceros BV, Yalelaan 46, 3584 CM Utrecht, The Netherlands, ‡German Diabetes Center, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany, and §Diabetes Center, VUMc, Postbus 7057, 1007 MB Amsterdam, The Netherlands

Figure S1 Total expression of Akt and downstream targets in cardiomyocytes is not altered upon HI and HP treatment in the absence or presence of anti-CD36-cl63

Cardiomyocytes were cultured in control, HI or HP medium in the absence or presence of 0.83 μg/ml anti-CD36-cl63. Upon 2 days culturing, cells were allowed to recover for 30 min prior to short-term (15 min) insulin (100 nM) addition and subsequent Western blot analysis of total Akt and GSK3β content. Hence, the changes in the phosphorylation states of these proteins (see Figure 5 of the main text) are not due to changes in total protein expression.

Figure S2 Washing steps after 48 h culturing almost entirely remove anti-CD36-cl63 used to detect the cell surface localization of CD36

Cardiomyocytes were cultured in control medium for 48 h in the presence of 0.83 μg/ml anti-CD36-cl63 (right-hand panel) and subsequently washed as described in the Materials and methods section of the main text (left-hand panel), and then used for microscopic detection of anti-CD36-cl63 using a FITC-labelled secondary antibody (n = 3). It is of note that, upon washing, the fluorescent signal has almost completely disappeared, indicating that the washing procedure effectively removes anti-CD36-cl63.

1 These authors contributed equally to this work.
2 To whom correspondence should be addressed (email y.angin@maastrichtuniversity.nl).
Figure S3  Binding to CD36 is not sufficient for anti-CD36 antibodies to prevent the maladaptive changes in cardiomyocytes upon exposure to lipotoxic conditions

(A) Anti-CD36-cl10E10 detects CD36 on Western blots. CD36 protein expression was checked in the homogenates from liver (negative control) and heart tissue by Western blotting. The ability of the anti-CD36-cl10E10 mAb to detect CD36 was compared with the anti-CD36 mAb MO25 routinely used for Western blotting. Cardiomyocytes were cultured in control, HI or HP medium in the absence (Basal) or presence of 1.7 μg/ml anti-CD36-cl10E10. (B) Upon 2 days culturing, cells were allowed to recover for 30 min prior to short-term (15 min) insulin (100 nM) addition and subsequent measurement of [3H]glucose uptake. (C) Upon 2 days culturing, cardiomyocytes were used for analysis of peak sarcomere shortening. Values are means ± S.E.M. (n = 3). *P < 0.05, insulin effect; #P < 0.05, medium effect; ∧P < 0.05, anti-CD36 effect. These data demonstrate that, in contrast with anti-CD36-cl63 (see Figures 4 and 7 of the main text), anti-CD36-cl10E10 does not induce the substrate switch to increased glucose uptake, and does not preserve contractile function in cardiomyocytes exposed to lipotoxic conditions. In conclusion, merely binding to CD36 is not sufficient for anti-CD36 antibodies to prevent or protect against lipid-induced contractile dysfunction.
CD36 inhibition prevents contractile dysfunction

Figure S4 AMPK stimulation does not increase glucose uptake in anti-CD36-cl63-treated cardiomyocytes

Cardiomyocytes were cultured in control medium in the absence or presence of 1.7 \( \mu \)g/ml anti-CD36-cl10E10. Upon 2 days culturing, cells were allowed to recover for 30 min prior to short-term (15 min) addition of insulin (100 nM) and/or the potent AMPK stimulator oligomycin (5 \( \mu \)M), and subsequent measurement of \(^{3}H\)glucose uptake. Values are means ± S.E.M. \((n=3)\). \(^{*}P<0.05\), insulin effect; \(\phi P<0.05\), oligomycin effect; \(^{\wedge}P<0.05\), anti-CD36 effect. These data demonstrate that short-term AMPK stimulation of anti-CD36-cl63-treated cardiomyocytes, in contrast with basally cultured cardiomyocytes, either in the absence or presence of short-term insulin stimulation, does not stimulate glucose uptake. We suggest that anti-CD36-cl63-treatment leads to a maximal depletion of GLUT4 from the intracellular storage compartment, so that additional treatment of cardiomyocytes with GLUT4 translocation-inducing stimuli will be futile.

Received 9 January 2012/14 June 2012; accepted 10 July 2012
Published as BJ Immediate Publication 10 July 2012, doi:10.1042/BJ20120060